건선성 관절염 치료 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of psoriatic arthritis treatment Market

The global psoriatic arthritis treatment market size was valued at USD 12.59 billion in 2025 and is projected to grow from USD 13.97 billion in 2026 to USD 32.11 billion by 2034, exhibiting a CAGR of 10.96% during the forecast period. North America dominated the market with a 43.78% share in 2025, supported by high adoption of biologic therapies, strong healthcare infrastructure, extensive research and development, and rapid regulatory approvals.

Psoriatic arthritis is a chronic autoimmune inflammatory condition affecting the joints and skin and is frequently associated with psoriasis. Rising disease prevalence, increasing awareness, improved diagnosis, growing healthcare expenditure, and the introduction of innovative biologic therapies are supporting the expansion of the psoriatic arthritis treatment market.

Market Definition and Scope

The psoriatic arthritis treatment market includes pharmaceutical therapies used to manage joint inflammation, pain, skin symptoms, and disease progression. Treatment options include non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic DMARDs, biologic DMARDs, and other therapies.

The market also covers treatment delivered through different administration routes, particularly oral and parenteral methods, along with distribution through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Increasing adoption of targeted biological treatments and biosimilars is further broadening the market landscape.

Market Dynamics

Drivers

The rising prevalence of psoriatic arthritis is a major factor driving market growth. Aging populations, stressful lifestyles, increasing psoriasis prevalence, longer life expectancy, and improved disease identification are contributing to a growing patient pool. The strong association between psoriasis and psoriatic arthritis is also increasing demand for effective treatment options.

Another important driver is the strong pipeline of innovative biologic drugs. Pharmaceutical companies are investing in targeted therapies designed to provide improved clinical outcomes. New product approvals and strategic collaborations are encouraging treatment innovation and increasing access to advanced therapies.

Trends

The growing penetration of biologic drugs is a prominent market trend. Traditional treatments have increasingly been complemented by targeted biologic and biosimilar therapies that address specific inflammatory pathways. Greater investment in research, clinical trials, and advanced treatment approaches is expected to strengthen biologic adoption.

The expansion of online pharmacies and telehealth services is another emerging trend, improving patient access to prescriptions and long-term treatment management.

Restraints

The high cost of biologic therapies remains a major restraint, particularly in developing countries where healthcare expenditure and reimbursement coverage may be limited. Adverse effects, delayed diagnosis, treatment-management gaps, stringent regulatory requirements, and patent expirations can also influence market growth.

Impact of COVID-19

The COVID-19 pandemic affected conventional healthcare access because patients requiring regular consultations faced restrictions and reduced hospital visits. However, the growing use of telehealth and online pharmacy services helped patients obtain consultations, prescriptions, and medications remotely. Although concerns existed regarding immunosuppressive therapies, healthcare providers continued to manage PsA patients through alternative care models, limiting the pandemic's long-term impact on the market.

Segmentation Analysis

By drug class, the market is divided into NSAIDs, non-biologic DMARDs, biologic DMARDs, and others. Biologic DMARDs are expected to dominate in 2026, supported by their effectiveness in controlling disease symptoms and increasing adoption of targeted therapies.

By route of administration, the market is categorized into oral and parenteral routes. The parenteral segment holds a leading position due to the widespread administration of biologic medicines through systemic and injectable methods.

By distribution channel, the market includes hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies are expected to hold the largest share of 61.70% in 2025, supported by the use of systemic therapies and access to specialized healthcare professionals. Online pharmacies are expected to experience strong growth because of convenience and increasing internet penetration.

Regional Insights

North America led the psoriatic arthritis treatment market with a 43.78% share in 2025. The region benefits from high adoption of biologic treatments, substantial pharmaceutical R&D expenditure, advanced healthcare infrastructure, and rapid regulatory approvals in the U.S.

Europe is supported by improving access to advanced therapies and increasing healthcare expenditure. Asia Pacific is expected to experience the highest growth, driven by improving healthcare infrastructure, increasing healthcare spending, growing disease awareness, and expanding access to biologic therapies. Japan is projected to reach a market value of USD 659.7 million by 2025, while China is expected to witness strong growth. Latin America and the Middle East & Africa are emerging markets with increasing treatment opportunities.

Competitive Landscape

The market is relatively consolidated, with major pharmaceutical companies competing through biologic launches, clinical development, regulatory approvals, and strategic collaborations. Key players include F. Hoffmann-La Roche Ltd, Novartis AG, Amgen, Pfizer Inc., Johnson & Johnson Services, Eli Lilly and Company, AstraZeneca, Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, and Bayer AG.

Key Industry Developments

In March 2019, AbbVie announced Japanese approval of SKYRIZI for several psoriasis-related indications, including psoriatic arthritis.

In October 2018, Novartis announced a European Commission label update for Cosentyx.

In December 2017, Pfizer received U.S. FDA approval for its infliximab biosimilar for several inflammatory conditions, including psoriatic arthritis.

Report Coverage

The report covers the global psoriatic arthritis treatment market size and forecast for 2025, 2026, and 2034, along with market dynamics, trends, growth drivers, restraints, COVID-19 impact, segmentation by drug class, route of administration and distribution channel, regional analysis, competitive landscape, leading companies, and major industry developments.

Conclusion

The global psoriatic arthritis treatment market, valued at USD 12.59 billion in 2025, is projected to reach USD 32.11 billion by 2034. Rising disease prevalence, expanding biologic treatment adoption, strong pharmaceutical pipelines, and increasing healthcare access will remain key growth factors. North America is expected to maintain its leading position, while Asia Pacific offers significant expansion opportunities. Continued development of targeted therapies, biosimilars, telehealth services, and convenient distribution channels is expected to strengthen the market outlook through 2034.

Unit Value (USD Billion)

Segmentation By Drug Class

• Non-steroidal Anti-inflammatory Drugs (NSAIDS)
• Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
• Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America (the U.S., and Canada)
• Europe (the U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• The Middle East & Africa (South Africa, GCC and the Rest of the Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Psoriatic Arthritis for Key Countries/Region
• 4.2. Recent Industry Developments Such as Partnerships, Mergers & Acquisitions, New Product Launches Etc.
• 4.3. Pipeline Analysis for Key Companies
• 4.4. Regulatory Framework by Key Countries
• 4.5. Impact of COVID-19 on Psoriatic Arthritis Treatment Market

5. Global Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 5.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
  • 5.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Topical
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Class
  • 6.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 6.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
  • 6.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
• 6.3. Market Analysis - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Topical
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online pharmacies
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Class
  • 7.2.1. Non-steroidal Anti-inflammatory Drugs
  • 7.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
  • 7.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
• 7.3. Market Analysis - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Topical
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online pharmacies
• 7.5. Market Analysis - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Class
  • 8.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 8.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
  • 8.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
• 8.3. Market Analysis - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Topical
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online pharmacies
• 8.5. Market Analysis - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Class
  • 9.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 9.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
  • 9.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
• 9.3. Market Analysis - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Topical
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online pharmacies
• 9.5. Market Analysis - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Class
  • 10.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 10.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • 10.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
• 10.3. Market Analysis - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Topical
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online pharmacies
• 10.5. Market Analysis - By Country/Sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. AbbVie Inc.
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products,
    • 11.3.1.3. SWOT,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Novartis AG
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products,
    • 11.3.2.3. SWOT,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. Johnson & Johnson Services, Inc.
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products,
    • 11.3.3.3. SWOT,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Pfizer Inc.,
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products,
    • 11.3.4.3. SWOT,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. LEO Pharma A/S
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products,
    • 11.3.5.3. SWOT,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Merck & Co., Inc.
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products,
    • 11.3.6.3. SWOT,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. Amgen Inc.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products,
    • 11.3.7.3. SWOT,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. Eli Lilly and Company
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products,
    • 11.3.8.3. SWOT,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)
  • 11.3.9. CELGENE CORPORATION
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products,
    • 11.3.9.3. SWOT,
    • 11.3.9.4. Recent developments,
    • 11.3.9.5. strategies,
    • 11.3.9.6. financials (based on availability)
  • 11.3.10. UCB S.A.
    • 11.3.10.1. Overview,
    • 11.3.10.2. Products,
    • 11.3.10.3. SWOT,
    • 11.3.10.4. Recent developments,
    • 11.3.10.5. strategies,
    • 11.3.10.6. financials (based on availability)
  • 11.3.11. Sun Pharmaceutical Industries Ltd.
    • 11.3.11.1. Overview,
    • 11.3.11.2. Products,
    • 11.3.11.3. SWOT,
    • 11.3.11.4. Recent developments,
    • 11.3.11.5. strategies,
    • 11.3.11.6. financials (based on availability)
  • 11.3.12. Other prominent players
    • 11.3.12.1. Overview,
    • 11.3.12.2. Products,
    • 11.3.12.3. SWOT,
    • 11.3.12.4. Recent developments,
    • 11.3.12.5. strategies,
    • 11.3.12.6. financials (based on availability)

12. Strategic Recommendations